News round-up for 11-15 November by DDW Senior Digital Content Editor Diana Spencer. With the Society for Immunotherapy of Cancer (SITC) 2024 taking place in Houston recently, there have been a number of recent announcements regarding the clinical advancement of immunocytokines, METTL3 inhibitors, cancer vaccines, CAR-T therapies and immune… Read More
New research has found that combining immunotherapy with chemotherapy is safe and effective for people with advanced small cell cancers in the bladder and prostate. A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with… Read More
The US Food and Drug Administration (FDA) has approved Autolus’ obecabtagene autoleucel (Aucatzyl), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). The efficacy of obecabtagene autoleucel was evaluated in FELIX, an open-label, multicentre, single-arm trial that enrolled adults… Read More
New data supporting SOT201, a PD-1-targeting immunocytokine, in advanced solid tumours was presented at the 2024 Society for Immunotherapy of Cancer (SITC) Meeting in Houston, TX, US. SOT201 is a PD-1-targeted and cis-acting attenuated IL-15 agonist designed to preferentially activate PD-1+CD8+ T cells, inducing superior anti-tumour… Read More
Diana Spencer speaks to Dr Wansu Qiu, Technical Account Manager at Sino Biological US, about how advances in engineering technologies are paving the way for improved antibody drugs. DS: Since 1986, the FDA has granted marketing authorisation to over 100 therapeutic antibodies, many in oncology. Why has this been a… Read More
Researchers have discovered that an eczema-linked protein helps ovarian cancer manipulate its environment to resist immunotherapy, suggesting the potential for a skin drug-based treatment. Scientists at the Icahn School of Medicine at Mount Sinai used spatial genomics technology and preclinical animal models, with tumour specimens from… Read More
DDW’s Megan Thomas speaks with Dr Chantale Bernatchez, Director of Cell Therapy Process Development at CTMC, about tumour infiltrating lymphocyte (TIL) therapy and what's on the horizon for this new class of cell therapy. TIL therapy is a form of cancer immunotherapy. It's an autologous cell therapy, meaning cells are… Read More
Akiram Therapeutics will reveal its research findings on radioimmunotherapy drug candidate AKIR001 at the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg, from 19-23 October. 177Lu-AKIR001 holds the potential to become a first-in-class treatment in multiple cancer types, including anaplastic and iodine-refractory thyroid cancer,… Read More
A team of UK universities, hospitals and industry, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust, have launched a new platform to understand immunotherapy response and side effects in cancer. The programme will be funded by £9 ($11.7) million from the… Read More
The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The publication of DDW’s latest eBook on immunotherapy has coincided… Read More
Biopharmaceutical companies OncoC4 and AcroImmune, both co-founded by CEO, Yang Liu and CMO, Pan Zheng, have entered into a definitive merger agreement. Under the terms of the agreement, OncoC4 will acquire 100% of the outstanding equity interests of AcroImmune. The merger expands OncoC4’s wholly owned immunotherapy pipeline with the addition… Read More
News round-up for 23-27 September by DDW Senior Digital Content Editor Diana Spencer. The publication of DDW’s latest eBook on immunotherapy has coincided with some interesting developments in this therapy area, particularly monoclonal antibodies, including two new regulatory approvals. The top stories: Innovent… Read More
Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases. These treatments leverage the body’s immune system to fight disease, spanning a range of different approaches, including immune checkpoint inhibitors, adoptive cell therapies, monoclonal antibodies, oncolytic virus therapy, cancer vaccines,… Read More
Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases. This eBook, sponsored by Sino Biological, examines the latest innovations that are driving the market and overcoming the challenges associated with these treatments.
Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have shown that a combination of treatments in mice with lung cancer allow immunotherapies to target non-responsive tumours. Their findings show that targeting tumours in different ways simultaneously might increase response to treatments. Read More
Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format. This week we have seen… Read More
